Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - omeprazole - gastro-resistant capsule, hard - 40 milligram(s) - proton pump inhibitors; omeprazole

Uingereza - Kiingereza - myHealthbox

salf spa laboratorio farmacologico - paracetamol - solution for infusion - 10mg - other analgesics and antipyretics - it is indicated for the shortterm treatment of moderate pain, especially following surgery and for the short-term treatment of fever, when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

chefaro ireland dac - nicotine - medicated chewing-gum - 2 milligram(s) - drugs used in nicotine dependence; nicotine - drugs used in nicotine dependence - niquitin medicated chewing gum is used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms including cravings during a quit attempt (see section 5.1). permanent cessation of tobacco use is the eventual objective.

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

chefaro ireland dac - nicotine - medicated chewing-gum - 2 milligram(s) - drugs used in nicotine dependence; nicotine - drugs used in nicotine dependence - niquitin fresh mint medicated chewing gum is used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms including cravings during a quit attempt. permanent cessation of tobacco use is the eventual objective.

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

chefaro ireland dac - nicotine - medicated chewing-gum - 4 milligram(s) - drugs used in nicotine dependence; nicotine - drugs used in nicotine dependence - niquitin fresh mint 4mg medicated chewing gum is used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms including cravings during a quit attempt . permanent cessation of tobacco use is the eventual objective.

Uingereza - Kiingereza - myHealthbox

omega pharma ltd - nicotine - medicated chewing gum - 2mg - niquitin fresh mint gum relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. it is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. niquitin fresh mint gum is indicated in pregnant and lactating women making a quit attempt. niquitin fresh mint gum should preferably be used in conjunction with a behavioural support programme.

Uingereza - Kiingereza - myHealthbox

omega pharma ltd - nicotine - medicated chewing gum - 4mg - niquitin fresh mint gum relieves and/or prevents craving and nicotine withdrawal symptoms associated with tobacco dependence. it is indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them. niquitin fresh mint gum is indicated in pregnant and lactating women making a quit attempt. niquitin fresh mint gum should preferably be used in conjunction with a behavioural support programme

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

mylan pharmaceuticals limited - aripiprazole - schizophrenia; bipolar disorder - psycholeptics - aripiprazole mylan pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.aripiprazole mylan pharma is indicated for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.aripiprazole mylan pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in bipolar i disorder in adolescents aged 13 years and older.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrel hydrochloride - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotic agents - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease., - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy., , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke., , for further information please refer to section 5.1. , , ,

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

teva pharma b.v.  - clopidogrel (as hydrobromide) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome: non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.